Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs.

By taking advantage of the cytotoxic effect of nitric oxide (NO) and PepT1 for molecule-targeted drug delivery, a series of amino acid/dipeptide diester prodrugs of NO-donating oleanolic acid derivatives were designed and synthesized. Two prodrugs 6a and 8a showed potent cytotoxcity, which is probably due to their high PepT1 affinity and NO-releasing ability. Furthermore, the aqueous solubility of the prodrugs was also significantly enhanced because of the hydrophilic amino acid/dipeptide promoiety.

[1]  K. Kashfi,et al.  NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals. , 2012, ACS medicinal chemistry letters.

[2]  A. W. Carpenter,et al.  Nitric oxide release: part II. Therapeutic applications. , 2012, Chemical Society reviews.

[3]  Jie Liu.  Oleanolic acid and ursolic acid: Research perspectives , 2005 .

[4]  D. Meredith,et al.  Modified amino acids and peptides as substrates for the intestinal peptide transporter PepT1. , 2000, European journal of biochemistry.

[5]  Q. Ping,et al.  Ethylene glycol-linked amino acid diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability and pharmacokinetics. , 2012, Molecular pharmaceutics.

[6]  S. Yoo,et al.  Dose‐linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats , 2007, Biopharmaceutics & drug disposition.

[7]  B. Vig,et al.  Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs , 2005, Molecular Cancer Therapeutics.

[8]  Q. Ping,et al.  Propylene glycol-linked amino acid/dipeptide diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability, and pharmacokinetics. , 2013, Molecular pharmaceutics.

[9]  M. Kirsch‐Volders,et al.  Studies of the potential genotoxic effects of furoxans: the case of CAS 1609 and of the water-soluble analogue of CHF 2363. , 2008, Toxicology letters.

[10]  Luyong Zhang,et al.  Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid. , 2010, Organic & biomolecular chemistry.

[11]  Elisabetta Marini,et al.  New nitric oxide or hydrogen sulfide releasing aspirins. , 2011, Journal of medicinal chemistry.

[12]  U. Testa,et al.  Triterpenoids as new promising anticancer drugs. , 2009, Anti-cancer drugs.

[13]  K. Kashfi,et al.  Nitric-oxide-donating NSAIDs as agents for cancer prevention. , 2004, Trends in molecular medicine.

[14]  Jie Liu.  Pharmacology of oleanolic acid and ursolic acid , 2003 .

[15]  G. Amidon,et al.  "5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter,". , 1999, Pharmaceutical research.

[16]  Jide Tian,et al.  Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid. , 2008, Journal of medicinal chemistry.

[17]  Alain Goossens,et al.  Oleanolic acid. , 2012, Phytochemistry.

[18]  M. Gumbleton,et al.  RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. , 2009, The Journal of pharmacy and pharmacology.

[19]  V. Ganapathy,et al.  Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. , 2000, Journal of pharmaceutical sciences.

[20]  M. Sporn,et al.  Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease , 2012, Pharmacological Reviews.

[21]  Ming Xian,et al.  Nitric oxide donors: chemical activities and biological applications. , 2002, Chemical reviews.